- Home
- FOLD
as 12-20-2024 4:00pm EST
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 2.9B | IPO Year: | 2007 |
| Target Price: | $16.71 | AVG Volume (30 days): | 2.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.35 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.02 - $14.57 | Next Earning Date: | 11-06-2024 |
| Revenue: | $493,671,000 | Revenue Growth: | 32.58% |
| Revenue Growth (this year): | 34.3% | Revenue Growth (next year): | 21.78% |
Stock Insider Trading Activity of Amicus Therapeutics Inc. (FOLD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Campbell Bradley L | FOLD | President and CEO | Dec 2 '24 | Sell | $10.02 | 7,500 | $75,124.50 | 886,654 | |
| Campbell Bradley L | FOLD | President and CEO | Nov 6 '24 | Sell | $12.50 | 7,901 | $98,800.42 | 886,654 | |
| Campbell Bradley L | FOLD | President and CEO | Nov 1 '24 | Sell | $11.46 | 7,500 | $85,959.75 | 886,654 | |
| Campbell Bradley L | FOLD | President and CEO | Oct 1 '24 | Sell | $10.60 | 7,500 | $79,492.50 | 886,654 |
Latest Amicus Therapeutics Inc. News
FOLD Breaking Stock News: Dive into FOLD Ticker-Specific Updates for Smart Investing
Benzinga
9 days ago
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
Zacks
9 days ago
Amicus Therapeutics (FOLD) is a Top-Ranked Momentum Stock: Should You Buy?
MT Newswires
9 days ago
Morgan Stanley Downgrades Amicus Therapeutics to Equalweight From Overweight, Cuts Price Target to $12 From $17
Zacks
16 days ago
Why Is Amicus Therapeutics (FOLD) Down 11.1% Since Last Earnings Report?
Zacks
17 days ago
HALO vs. FOLD: Which Stock Is the Better Value Option?
Simply Wall St.
19 days ago
Exploring High Growth Tech Stocks In The United States December 2024
Zacks
a month ago
HALO vs. FOLD: Which Stock Should Value Investors Buy Now?
Simply Wall St.
a month ago
Amicus Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Compare FOLD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FOLD Amicus Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.